[1]方年富,何慶霞,楊衛生,等.胃蛋白酶原與胃泌素-17在胃癌前病變篩查中的價值[J].醫學信息,2019,(22):170-171.[doi:10.3969/j.issn.1006-1959.2019.22.060]
 FANG Nian-fu,HE Qing-xia,YANG Wei-sheng,et al.The Value of Pepsinogen and Gastrin-17 in the Screening of Gastric Precancerous Lesions[J].Medical Information,2019,(22):170-171.[doi:10.3969/j.issn.1006-1959.2019.22.060]
點擊復制

胃蛋白酶原與胃泌素-17在胃癌前病變篩查中的價值()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
170-171
欄目:
診療技術
出版日期:
2019-11-15

文章信息/Info

Title:
The Value of Pepsinogen and Gastrin-17 in the Screening of Gastric Precancerous Lesions
文章編號:
1006-1959(2019)22-0170-02
作者:
方年富何慶霞楊衛生賈克紅袁光勇余恕玉
(江西省景德鎮市第二人民醫院消化內科,江西 景德鎮 333000)
Author(s):
FANG Nian-fuHE Qing-xiaYANG Wei-shengJIA Ke-hongYUAN Guang-yongYU Shu-yu
(Department of Gastroenterology,the Second People's Hospital of Jingdezhen,Jingdezhen 333000,Jiangxi,China)
關鍵詞:
胃癌胃蛋白酶原胃泌素-17癌前病變
Keywords:
Gastric cancerPepsinogenGastrin-17Precancerous lesions
分類號:
R735.2
DOI:
10.3969/j.issn.1006-1959.2019.22.060
文獻標志碼:
A
摘要:
目的 探討血清胃蛋白酶原Ⅰ、Ⅱ(PGⅠ、Ⅱ)與胃泌素-17(G-17)在胃癌前病變中的診斷價值。方法 回顧性分析2018年1月~10月我院收治的消化道患者98例,根據胃鏡檢查及病理結果分為胃潰瘍組32例、萎縮性胃炎組21例、腸上皮化生組25例、低級別上皮內瘤變組20例,另選取同期我院檢查的健康體檢者30名作為對照組。應用ELISA法檢測比較五組血清PGⅠ、PGⅡ、胃蛋白酶原比值PGR,(PGI/PGⅡ)、G-17水平。結果 與對照組比較,胃潰瘍組PGⅠ、PGⅡ、G-17升高[(131.83±24.62)μg/L vs(95.29±23.47)μg/L]、[(15.31±6.65)μg/L vs(10.93±2.35)μg/L]、[(15.34±4.22)pmol/L vs(9.31±2.48)pmol/L],萎縮性胃炎組、腸上皮化生組、低級別上皮內瘤變組PGⅠ、PGR降低,差異有統計學意義(P<0.05)。結論 血清PGⅠ、PGR、G-17可作為胃癌及其癌前病變篩查的指標。
Abstract:
Objective To investigate the diagnostic value of serum pepsinogen Ⅰ, Ⅱ (PGⅠ, Ⅱ) and gastrin-17 (G-17) in precancerous lesions. Methods A retrospective analysis of 98 patients with digestive tract admitted to our hospital from January to October 2018 was performed. According to the results of gastroscopy and pathology, there were 32 patients with gastric ulcer, 21 patients with atrophic gastritis, and 25 patients with intestinal metaplasia. Twenty patients with low-grade intraepithelial neoplasia were enrolled, and 30 healthy subjects examined in our hospital were selected as the control group. Five groups of serum PGⅠ, PGⅡ pepsin ratio PGR, (PGⅠ/PGⅡ) and G-17 levels were compared by ELISA. Results Compared with the control group, PGⅠ, PGⅡ, and G-17 were elevated in the gastric ulcer group [(131.83±24.62) μg/L vs (95.29±23.47) μg/L], [(15.31±6.65) μg/L vs (10.93± 2.35) μg/L], [(15.34±4.22) pmol/L vs (9.31±2.48) pmol/L], PGⅠ and PGR were decreased in atrophic gastritis group, intestinal metaplasia group and low-grade intraepithelial neoplasia group,the difference was statistically significant (P<0.05). Conclusion Serum PGⅠ, PGⅡ and G-17 can be used as indicators for screening gastric cancer and its precancerous lesions.

參考文獻/References:

[1]馬英睿,左贊,郭強.血清胃功能檢測對萎縮性胃炎診斷及胃癌風險評估的研究進展[J].昆明醫科大學學報,2018,39(8):124-128. [2]中華消化雜志編委會.消化性潰瘍診斷與治療規范(2016年,西安)[J].中華消化雜志,2016,36(8):508-513. [3]中華醫學會病理分會消化病理學組籌備組.慢性胃炎及上皮性腫瘤胃黏膜活檢病理診斷共識[J].中華病理學雜志,2017,46(5):289-293. [4]Al-Rawashdeh O,Ismail ZB,Talafha A,et al.Changes of hematological and biochemical parameters and levels of pepsinogen, histamine and prostaglandins in dairy cows affected with left displacement of the abomasum[J].Pol J Vet Sci,2017,20(1):13-18. [5]陳春春,羅和生,成鍍,等.血清胃蛋白酶原在慢性胃部病變中變化的臨床研究[J].胃腸病學和肝病學雜志,2018,27(11):1265-1269. [6]陳莫耶,徐倩,孫麗萍,等.血清胃泌素17水平與胃癌及癌前疾病的相關性研究[J].胃腸病學和肝病學雜志,2015,24(2):161-165.

相似文獻/References:

[1]尹曉華,劉重元,黃 琳,等.胃癌中lncRNAs的研究進展[J].醫學信息,2018,(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
 YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,(22):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小華,等.基質金屬蛋白酶2與蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究進展[J].醫學信息,2018,(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
 RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Medical Information,2018,(22):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化療并發嗜血細胞綜合征患者的護理[J].醫學信息,2018,(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
 DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Medical Information,2018,(22):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理會,李育莊,李春輝.胃癌與高凝血狀態關系的研究現狀[J].醫學信息,2018,(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
 PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Medical Information,2018,(22):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]茅溢恒.幽門螺桿菌抗體、胃泌素17、胃蛋白酶原等聯合檢測 在體檢人群胃疾病篩查中的意義[J].醫學信息,2018,(11):22.[doi:10.3969/j.issn.1006-1959.2018.11.007]
 MAO Yi-heng.The Significance of Combined Detection of Helicobacter Pylori Antibody,Gastrin 17, Pepsinogen,etc.in Gastric Disease Screening in Physical Examination Population[J].Medical Information,2018,(22):22.[doi:10.3969/j.issn.1006-1959.2018.11.007]
[6]梁延洋,程艷娜,華柏慧,等.胃癌合并2型糖尿病術后血糖改善的臨床觀察[J].醫學信息,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,(22):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[7]林躍韓,許慶文.腹腔鏡uncut Roux-en-Y吻合與傳統吻合方式的研究進展[J].醫學信息,2018,(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
 LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Medical Information,2018,(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[8]馬玉濤,石文娜,李曉林,等.免疫熒光法檢測FSHR與GnRHR在胃癌組織中的分布及其共定位研究[J].醫學信息,2018,(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
 MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Medical Information,2018,(22):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[9]潮子健,汪文生,謝宏偉.年齡對胃部常見良性疾病患者的胃蛋白酶原及胃泌素-17水平的影響[J].醫學信息,2018,(23):105.[doi:10.3969/j.issn.1006-1959.2018.23.028]
 CHAO Zi-jian,WANG Wen-sheng,XIE Hong-wei.Effect of Age on Pepsinogen and Gastrin-17 Levels in Patients with Common Benign Diseases of the Stomach[J].Medical Information,2018,(22):105.[doi:10.3969/j.issn.1006-1959.2018.23.028]
[10]趙 靜.血漿纖維蛋白原和CA724水平在胃癌患者的變化及臨床意義[J].醫學信息,2018,(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
 ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Medical Information,2018,(22):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩